• Radiation Therapy
      • Treatment Delivery
        • Elekta Unity Elekta Unity
        • Versa HD Versa HD
        • Elekta Harmony Elekta Harmony
        • Elekta Infinity Elekta Infinity
        • Elekta Synergy Elekta Synergy
      • Treatment Management
        • Monaco
        • ProKnow
      • Quality Assurance
        • Machine QA
        • Patient QA
    • Stereotactic Radiosurgery
      • Delivery
        • Elekta Esprit Elekta Esprit
        • Leksell Gamma Knife Icon Leksell Gamma Knife Icon
        • Leksell Gamma Knife Perfexion Leksell Gamma Knife Perfexion
        • Versa HD Versa HD
      • Treatment Planning
        • Leksell Gamma Knife Lightning
        • Leksell GammaPlan
    • Oncology Informatics
      • MOSAIQ Plaza
        • Subscribe to Better
        • Professional Services
        • Interoperability
      • Elekta Axis Cloud
    • Brachytherapy
      • Delivery
        • Elekta Studio Elekta Studio
        • ImagingRing ImagingRing
        • Oncentra Brachy Oncentra Brachy
        • Venezia Venezia
        • Flexitron Flexitron
        • Geneva Geneva
      • Body Sites
        • Head and Neck
        • Bronchus and Oesophagus
        • Breast
        • Skin
        • Prostate
        • Rectum
        • Bladder
        • Gynecology
    • Neurosurgery
      • Delivery
        • Leksell Vantage Stereotactic System Leksell Vantage Stereotactic System
        • Leksell Stereotactic System Leksell Stereotactic System
    • Veterinary Radiation Therapy
    • Elekta Care Customer Services
    • Elekta Care 360
    • Elekta Care Learning
    • Elekta Care Community
    • Elekta Partner Community
    • MR-Linac Treatment
    • Brachytherapy Treatment
    • Gamma Knife Treatment
    • Radiation Therapy Treatment
    • Treatment Centers
    • Company
    • Partnering with Elekta
    • About us
      • About us
        • Board of Directors
        • Code of Conduct
        • Corporate Citizenship
        • Executive Management
        • Integrity Line
        • Programs
        • Sponsorship and Donation
        • Story
    • Sustainability
    • Corporate Governance
      • Corporate Governance
        • Shareholders’ meetings
          • Board of Directors
            • Executive Management
              • Auditors
              • Reports
          • Investors
            • Investors
              • Investment case
                • Outlook
                • The share
                  • Financials
                    • Funding
                      • Reports & presentations
                      • Press releases
                      • IR calendar
                      • IR contacts
                  • Newsroom
                    • Newsroom
                      • Press Releases
                      • FOCUS Magazine
                      • Events
                      • Image bank
                  • Careers at Elekta
                    • Jobs
                  • Reimbursement Support & Policy
                ENSV
                Login
                • Products
                  • Radiation Therapy
                    • Treatment Delivery
                      • Elekta Unity
                      • Versa HD
                      • Elekta Harmony
                      • Elekta Infinity
                      • Elekta Synergy
                    • Treatment Management
                      • Monaco
                      • ProKnow
                    • Quality Assurance
                      • Machine QA
                      • Patient QA
                  • Stereotactic Radiosurgery
                    • Delivery
                      • Elekta Esprit
                      • Leksell Gamma Knife Icon
                      • Leksell Gamma Knife Perfexion
                    • Treatment Planning
                      • Leksell Gamma Knife Lightning
                      • Leksell GammaPlan
                    • Versa HD
                  • Oncology Informatics
                    • MOSAIQ Plaza
                      • Subscribe to Better
                      • Professional Services
                      • Interoperability
                    • Elekta Axis Cloud
                  • Brachytherapy
                    • Elekta Studio
                    • ImagingRing
                    • Venezia
                    • Flexitron
                    • Geneva
                    • Head and Neck
                    • Bronchus and Oesophagus
                    • Breast
                    • Skin
                    • Prostate
                    • Rectum
                    • Bladder
                    • Gynecology
                    • Oncentra Brachy
                  • Neurosurgery
                    • Leksell Vantage Stereotactic System
                    • Leksell Stereotactic System
                  • Veterinary Radiation Therapy
                • Services
                  • Elekta Care Customer Services
                  • Elekta Care 360
                  • Elekta Care Learning
                  • Elekta Care Community
                  • Elekta Partner Community
                • Patients
                  • MR-Linac Treatment
                  • Brachytherapy Treatment
                  • Gamma Knife Treatment
                  • Radiation Therapy Treatment
                  • Treatment Centers
                • Company
                  • Partnering with Elekta
                  • About us
                    • Board of Directors
                    • Code of Conduct
                    • Corporate Citizenship
                    • Executive Management
                    • Integrity Line
                    • Programs
                    • Sponsorship and Donation
                    • Story
                  • Sustainability
                  • Corporate Governance
                    • Shareholders’ meetings
                      • Board of Directors
                        • Executive Management
                          • Auditors
                          • Reports
                        • Investors
                          • Investment case
                            • Outlook
                            • The share
                              • Financials
                                • Funding
                                  • Reports & presentations
                                  • Press releases
                                  • IR calendar
                                  • IR contacts
                                • Newsroom
                                  • Press Releases
                                  • FOCUS Magazine
                                  • Events
                                  • Image bank
                                • Careers at Elekta
                                  • Jobs
                                • Reimbursement Support & Policy
                              • Contact
                              • Medical Affairs
                              • Regulatory Affairs
                              • Suppliers
                                • About Elekta Procurement
                                • Sustainable Sourcing
                                • Performance Management
                                  • Production Part Approval Process
                                  • Supplier Escalation Form
                                  • Non Conformance Management
                                  • Supplier Performance Management
                                  • Obsolescence Management
                                • Compliance Management
                                • Invoicing Process
                                • Elekta T&C
                                • Documents & Training
                                • Our Global Presence
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube

                              Interim report, May–January 2022/23

                              February 24, 2023

                              Growth and improved margins

                              Demand for radiotherapy continued to improve in the quarter and supported our order growth. We managed the supply chain challenges well and strong installation volumes at the end of the quarter increased revenue. The Cost-reduction Initiative is progressing according to plan, supporting profitable growth going forward.

                              Gustaf Salford
                              President and CEO

                              Third quarter
                              • Gross order intake amounted to SEK 5,316 M (4,441), corresponding to a 9 percent increase in constant exchange rates
                              • Net sales were SEK 4,337 M (3,602), corresponding to an 8 percent increase in constant exchange rates
                              • Adjusted gross margin amounted to 38.4 percent (36.7)
                              • Adjusted EBIT amounted to SEK 463 M (340), corresponding to an adjusted EBIT margin of 10.7 percent (9.4)
                              • Earnings per share was SEK 0.57 (0.60) before dilution and SEK 0.56 (0.60) after dilution
                              • Adjusted earnings per share was SEK 0.84 (0.60) before dilution and SEK 0.83 (0.60) after dilution
                              • Cash flow after continuous investments amounted to SEK -163 M (187)

                              First nine months
                              • Gross order intake amounted to SEK 13,785 M (12,467), corresponding to a 2 percent decrease in constant exchange rates
                              • Net sales were SEK 11,745 M (10,309), corresponding to a 2 percent increase in constant exchange rates
                              • Adjusted gross margin amounted to 38.2 percent (37.5)
                              • Adjusted EBIT amounted to SEK 911 M (1,074), corresponding to an adjusted EBIT margin of 7.8 percent (10.4)
                              • Earnings per share was SEK 1.04 (1.93) before dilution and SEK 1.04 (1.93) after dilution
                              • Adjusted earnings per share was SEK 1.58 (1.93) before dilution and SEK 1.58 (1.93) after dilution
                              • Cash flow after continuous investments amounted to SEK -1,174 M (-173)

                              Significant events

                              Third quarter
                              First patient treated with motion management using Unity
                              In December, the first patients completed their full course of radiation therapy treatment with Elekta Unity MR-Linac using Comprehensive Motion Management (CMM) with True Tracking and automatic gating functionalities at University Medical Center (UMC) Utrecht. 

                              Second quarter[1]
                              • Elekta’s Nomination Committee for AGM 2023
                              • Elekta Care 360 launched
                              • CE mark for CMM with True Tracking and automatic gating
                              • Elekta wins majority of Italian public tender
                              • Elekta Esprit receives CE mark and FDA clearance
                              • AGM 2022 approves dividend and new Board member
                              • Changes in Executive Management (Andrew Wilson, Karin Svenske Nyberg)

                              First quarter1
                              • New radiosurgery system Elekta Esprit launched
                              • Elekta and the Netherlands Cancer Institute to co-develop the next generation of radiotherapy solutions
                              • Elekta's Nomination Committee’s proposal to the AGM
                              • Changes in Executive Management (Carlos Castilleja)

                              [1] For more details about the previous significant events please see respective quarterly report.

                              Group summaryQ3First nine months
                              SEK M2022/232021/22Δ2022/232021/22Δ
                              Gross order intake5,3164,4419%113,78512,467-2%1
                              Net sales4,3373,6028%111,74510,3092%1
                              Adjusted gross margin 238.4%36.7%1.6 ppts 38.2%37.5%0.7 ppts 
                              Adjusted EBIT 346334036%9111,074-15%
                              Adjusted EBIT margin 310.7%9.4%1.3 ppts7.8%10.4%-2.7 ppts
                              Gross margin38.1%36.7%1.3 ppts37.6%37.5%0.1 ppts
                              EBIT331340-3%6471,074-40%
                              EBIT margin7.6%9.4%-1.8 ppts5.5%10.4%-4.9 ppts
                              Cash flow after continous investments-163187-188%-1,174-173-578%
                              Adjusted earnings per share before/after dilution, SEK4 0.84/0.830.60/0.6039%1.58/1.581.93/1.93-18%
                              Earnings per share before/after dilution, SEK 0.57/0.560.60/0.60-6%1.04/1.041.93/1.93-46%

                              1 Compared to last fiscal year based on constant exchange rates.
                              2 Adjusted gross margin = Gross margin excluding items affecting comparability attributable to the Cost-reduction
                              Initiative within the Resilience and Excellence Program, see page 26.
                              3 Adjusted EBIT = Operating income (EBIT) excluding items affecting comparability attributable to the Cost-reduction
                              Initiative within the Resilience and Excellence Program, see page 27.
                              4 Adjusted earnings per share = Net income attributable to Parent Company shareholders, excluding items affecting
                              comparability attributable to the Cost-reduction Initiative, in relation to the weighted average number of shares
                              (excluding treasury shares), see page 27.

                              # # #

                              For further information, please contact:
                              Cecilia Ketels, Head of Investor Relations
                              Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
                              Time zone: CET: Central European Time

                              Tobias Hägglöv, CFO
                              Tel: +46 76 107 47 99, e-mail: tobias.hagglov@elekta.com
                              Time zone: CET: Central European Time

                              About Elekta
                              As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don't just build technology, we build hope. Elekta is headquartered in Stockholm, Sweden, with offices in more than 40 countries and listed on Nasdaq Stockholm. For more information, visit elekta.com (http://www.elekta.com/) or follow @Elekta (https://twitter.com/Elekta) onTwitter.

                              This information is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2023-02-24 07:30 CET.

                              Attachments


                              Elekta Q3 Report 22 23

                              Downloads

                              • Elekta Q3 Report 22 23
                              • Products
                                • Radiation Therapy
                                • Stereotactic Radiosurgery
                                • Oncology Informatics
                                • Brachytherapy
                                • Neurosurgery
                                • Veterinary Radiation Therapy
                              • Services
                                • Elekta Care Customer Services
                                • Elekta Care 360
                                • Elekta Care Learning
                                • Elekta Care Community
                                • Elekta Partner Community
                              • Patients
                                • MR-Linac Treatment
                                • Brachytherapy Treatment
                                • Gamma Knife Treatment
                                • Radiation Therapy Treatment
                                • Treatment Centers
                              • Company
                                • Partnering with Elekta
                                • About us
                                • Sustainability
                                • Corporate Governance
                                • Investors
                                • Newsroom
                                • Careers at Elekta
                                • Country and regional pages
                                • Digital Product Security
                                • Offices
                              • Facebook
                              • LinkedIn
                              • Twitter
                              • Instagram
                              • Youtube
                              • ©2023 Elekta
                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.

                              © 2023 Elekta

                              • Legal notices
                              • Privacy policy
                              • Cookies
                              • Subscription center

                              Important Safety Information: Radiation therapy is not appropriate for all patients. Radiation treatments may cause side effects that can vary depending on the part of the body being treated. In some patients, they can be severe. Treatment sessions may vary in complexity and time. Refer to individual product labeling (instructions for use) for more complete information on product safety and effectiveness for its intended use.